News
(4)April 2026
IMUX Executes 1-for-10 Reverse Stock Split on April 27
# 🧾 What This Document Is This is an **8-K filing**, a "current report" that companies must file with the SEC to announce major events that shareholders should know about. Immunic is announcing a **1-for-10 reverse stock split** of its common stock. The filing includes the official legal amendment
IMUX files 1-for-10 reverse stock split after shareholder approval
# 📰 What This Document Is 📂 This document is an Amendment No. 1 to Immunic, Inc.'s Annual Report on Form 10-K. Think of a 10-K as the company's comprehensive, required annual report card, and this amendment is like a correction—it's being filed to update and include critical corporate governance i
IMMUNIC, INC. — 8-K Filing
# 🧾 What This Document Is This is an 8-K filing, which is a report companies use to announce major news to investors. In this case, Immunic is sharing official notice from Nasdaq that it has fixed a problem and is no longer at risk of being removed from the stock exchange. # 🚨 The Core Announceme
March 2026
IMMUNIC, INC. — 8-K Filing
# 🔖 What This Document Is This is an **8-K filing**, which is a report a company files with the SEC to announce major, shareholder-affecting news. In this case, **Immunic, Inc. (IMUX)** is announcing a key addition to its leadership team. Think of it as a formal press release with regulatory weight
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.